TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06383715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy Workshop for Content Moderators
Description: This 4-session group workshop is based on the principles of Cognitive Behavioral Therapy. It consists of four sessions:~1. Presentation. Scientific evidence of psychological consequences on content moderatos. Psicoeducation on the effects of vicarious trauma exposure.~2. Presentation of the cognitive model. Identification/operationalization of thoughts. Discussion of possible irrational thoughts.~3. Psychoeducation of emotions and their adaptive function. Behavioral strategies of emotions: exposure therapies and behavioral activation.~4. The role of social support. Strategies for appropriate work and sleep hygiene. Strategies for maintaining gains. Farewell.
Study: NCT06078813

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: image guided dose escalated SABR using a simultaneous integrated boost (SIB)
Description: Treatment will consist of image guided dose escalated SABR using a simultaneous integrated boost (SIB) delivered in two fractions adhering to organ at risk dose-volume histogram constraints. There will be three dose levels delivered to the Planning Target Volume_1 (PTV_1) in each treatment arm as follows: 28 Gy (14 Gy per fraction), 30 Gy (15 Gy per fraction) and 32 Gy (16 Gy per fraction). A lower dose of 20 Gy (10 Gy per fraction) will be delivered to the PTV_2 which will be defined according to international consensus guidelines (Cox et al., 2012). The dose to PTV_2 will remain the same through all dose levels. All doses are prescribed to the target volume.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: image guided dose escalated SABR using a simultaneous integrated boost (SIB)
Description: Treatment will consist of image guided dose escalated SABR using a simultaneous integrated boost (SIB) delivered in two fractions adhering to organ at risk dose-volume histogram constraints. There will be three dose levels delivered to the Planning Target Volume_1 (PTV_1) in each treatment arm as follows: 28 Gy (14 Gy per fraction), 30 Gy (15 Gy per fraction) and 32 Gy (16 Gy per fraction). A lower dose of 20 Gy (10 Gy per fraction) will be delivered to the PTV_2 which will be defined according to international consensus guidelines (Cox et al., 2012). The dose to PTV_2 will remain the same through all dose levels. All doses are prescribed to the target volume.
Study: NCT06423118

Intervention type: DEVICE
Intervention: ANNE Vital Sign System
Description: The ANNE Vital Sign System is a pair of non-invasive, flexible sensors originally designed for vital signs monitoring in the paediatric intensive care unit.
Study: NCT06046989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Emotion Awareness and Mental Health (BEAM)
Description: BEAM is based on best-practices in telehealth and science-based program design principles aimed at promoting parental mental health and supportive parenting. The BEAM Program mobile application is designed and managed by MindSea. The weekly one-on-one check-ins with peer coaches (parents who previously participated in another research group-based mental health intervention) will use the secure videoconferencing platform Zoom (Healthcare license) and direct messaging through the BEAM app. Peer coaches will also engage with participants on the community peer support forum. Monthly drop-in group peer support sessions will be facilitated by peer coaches and/or mental health professionals on the BEAM research team. The BEAM program's content emphasizes self-compassion, effective communication practices, and building social support networks.
Study: NCT04932421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Detectives: Unified protocol for transdiagnostic treatment of emotional disorders in children (UP-C)
Description: UP-C is a transdiagnostic and emotion-focused cognitive-behavioral group intervention for children aged 6-13 years old with emotions disorders (i.e., anxious and/or mood disorders) and their parents. UP-C unifies cognitive-behavioral, contextual (eg. mindfulness) and parental training techniques aiming to reduce the intensity and frequency of children's clinical symptomatology.~The intervention consists of 15 weekly group sessions (90 minutes per session; 5-8 children and parents per group) conducted by at least two clinical psychologists trained in the UP-C. The sessions start with the parents and children together (15 minutes); then, one psychologist conduct the session with the group of children while the other psychologist conduct the session with the group of parents, simultaneously (60 minutes); finally, the session ends with the group together (15 minutes). This is a structured and manualized intervention with a manual for the therapist and a workbook for the child and parents.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ABC of Emotions
Description: ABC of Emotions is a psychoeducational group intervention for children with anxiety and/or mood disorders, aged between 6 to 13 years. ABC of Emotions consists of 5 group psychoeducation sessions (about 90 minutes per session; 5-8 children per group). This is a structured and manualized intervention, with a manual for the therapist and a workbook for the child.~The contents of the sessions were developed by the researchers of this study and are based on classic psychoeducational cognitive-behavioral therapies (CBT) strategies. Since anxiety disorders are more frequent in childhood than mood disorders (e.g., Merikangas et al., 2009), this program is essentially based on psychoeducation materials focused on emotions such as anxiety and fear. However, the same materials are available in an attachment, adapted for use with children to whom the main emotion is not fear/anxiety, but sadness (as in mood disorders).
Study: NCT06583226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge stabilization with suture and cyanoacrylate
Description: The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge stabilization with suture and cyanoacrylate and coconut oil application
Description: Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) and coconut oil (test group)
Study: NCT05091970

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manualized cognitive rehabilitation for mild traumatic brain injury (mTBI)
Description: Three 60-minute sessions per week with a minimum of 6 sessions and a maximum of 10 sessions. This intervention is to be delivered by trained Occupational Therapists (OTs) and Speech-Language Pathologists (SLPs), and includes training in compensatory strategies, direct training of cognitive subskills (e.g., attention training), and assigned homework to practice skills learned in treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manualized cognitive rehabilitation for mild traumatic brain injury (mTBI)
Description: Three 60-minute sessions per week with a minimum of 6 sessions and a maximum of 10 sessions. This intervention is to be delivered by trained Occupational Therapists (OTs) and Speech-Language Pathologists (SLPs), and includes training in compensatory strategies, direct training of cognitive subskills (e.g., attention training), and assigned homework to practice skills learned in treatment.
Study: NCT05492097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Traditional exercise therapy and NMES

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy and Robotic Walking Training
Description: Traditional exercise therapy and Robotic Walking Training
Study: NCT05547321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMTX705
Description: The investigational product is OMTX705 administered as monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMTX705
Description: The investigational product is OMTX705 administered as monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The investigational product is OMTX705 administered in combination with pembrolizumab.
Study: NCT05522465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 4mg/kg.d, d1-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 0.6mg/kg.d, d1-4
Study: NCT06175871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTAGO exercises
Description: Exercices for improvement postural control and mobility and decrease falls risks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Exercice and education from physical therapy practice conventional from Hospital.
Study: NCT04433858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: open-label
Study: NCT05980637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shaoyao Gancao Decoction with Addition
Description: 11g twice daily for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 11g twice daily for 4 weeks
Study: NCT05788484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-585
Description: CDX-585 is administered by infusion every 2 weeks
Study: NCT04867668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-vaping and anti-smoking digital advertising
Description: Delivery of social media based advertising to prevent vaping and smoking among young adults ages 18-24.
Study: NCT04830813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
Study: NCT04679077

Intervention type: OTHER
Group type: OTHER
Intervention: Cytocam-IDF imaging device
Description: Observation of the microcirculation
Study: NCT06468189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct stimulation
Description: Mars-01(Marslab, Turkey) transcranial direct current stimulation device works with a 9 volt battery and consists of two 5x5 (25 cm2) electrodes (anode and cathode). 3 consecutive sessions (days), cathodal to occipital cortex (O1 or O2, ipsilateral); Anodal application will be made to M1 (left). Active stimulation is 2mA tDCS with a 0 to 30 second acceleration period of 20 minutes per session. Placebo stimulation will be applied according to the device's own sham software protocol. Accordingly, the current consists of 30 seconds of increase from 0 to 2mA(milliamp), 10 seconds of stimulation, 30 seconds of decrease to 0 and 20 minutes of current-free application.
Study: NCT05187104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured retinal stem and progenitor cells
Description: Cultured retinal stem and progenitor cells injected subretinally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of age-related macular degeneration according to the clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of age-related macular degeneration according to the clinical protocols
Study: NCT06468189

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: The same device used for stimulation will be used, but no stimulation will be given.
Study: NCT05702190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opium tincture
Description: Self-administration of opium tincture (10 mg/ml) as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administration of placebo as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
Study: NCT06220123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2004
Description: Investigational product arm: SHR-2004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium Injection; Rivaroxaban Tablets
Description: Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets
Study: NCT06516211

Intervention type: DEVICE
Intervention: Clara Pregnancy Test
Description: Multi-Level Pregnancy Test
Study: NCT04613752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diaphragmatic function measurements and diaphragmatic ultrasound
Description: A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
Study: NCT05588297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapOx(Capecitabine+ Oxaliplatin)
Description: CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles
Study: NCT06111599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar sympathetic blockade
Description: Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar sympathetic blockade
Description: Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar sympathetic blockade
Description: Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic
Study: NCT05921734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF-termination Group
Description: Each center completes the ablation according to the above ablation procedure. The choice of ablation strategy is not restricted, but efforts should be made to achieve termination of AF during the ablation procedure. If cannot terminate AF for safety or other reasons involving difficulties to remap AFEGM or creating a complete conduction block despite the operator's best efforts, then direct current conversion (DCCV) was performed.
Study: NCT04876261

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oliphenolia® bitter
Description: * ingredients: concentrated watery extract of olives 94%, lemon juice 6%~* 35 mg hydroxytyrosol, 0,24 mg Oleuropein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oliphenolia® bitter
Description: * ingredients: concentrated watery extract of olives 94%, lemon juice 6%~* 35 mg hydroxytyrosol, 0,24 mg Oleuropein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oliphenolia® bitter
Description: * ingredients: concentrated watery extract of olives 94%, lemon juice 6%~* 35 mg hydroxytyrosol, 0,24 mg Oleuropein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oliphenolia®
Description: * ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30%~* 38 mg hydroxytyrosol, 0,28 mg Oleuropein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oliphenolia®
Description: * ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30%~* 38 mg hydroxytyrosol, 0,28 mg Oleuropein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oliphenolia®
Description: * ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30%~* 38 mg hydroxytyrosol, 0,28 mg Oleuropein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol
Description: * extra virgin olive oil~* 5 mg hydroxytyrosol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol
Description: * extra virgin olive oil~* 5 mg hydroxytyrosol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol
Description: * extra virgin olive oil~* 5 mg hydroxytyrosol
Study: NCT05921734

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prespecified-ablation Group
Description: Each center completes the prespecified ablation according to the above ablation procedure. Although there is no restriction on the choice of ablation strategy, Ablation must be performed following the PVI plus strategy, which can be combined with one or more additional ablation procedures, but each ablation must achieve its own endpoints, such as bidirectional block of linear damage, posterior wall isolation, etc. After completing the preset ablation steps, DCCV will be performed. If AF is terminated after or during ablation, it is also considered the endpoint of ablation in this group, but the preset ablation steps must be completed.
Study: NCT06516211

Intervention type: DEVICE
Intervention: Clara Pregnancy Test
Description: Multi-Level Pregnancy Test

Intervention type: DEVICE
Intervention: Professional Marketed Pregnancy Test
Description: Early Pregnancy Test
Study: NCT05247801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention for safe medication use at home + Medication dosing device
Description: The intervention is yet to be defined. Psychoeducational intervention based on virtual reality, demonstrations, and psychoeducational content using virtual reality. Contents:~Most frequent medication errors at home. Approaches to risk management in the home. Correct use of the most common medications in different patient profiles. Strategies to avoid medication errors. Guidance to alleviate the burden of responsibility suffered by women as a result of the gender bias derived from assuming the caregiver role.~Other.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medication dosing device
Description: Use of medication dosing device.
Study: NCT06117163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care Model
Description: The investigators propose a CCM called Tunawiri, meaning thrive in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics. CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression, and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication.
Study: NCT04701931

Intervention type: DEVICE
Intervention: Maestro2 OCTA
Description: The Maestro2 OCTA with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes

Intervention type: DEVICE
Intervention: Maestro2 OCTA
Description: The Maestro2 OCTA with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes

Intervention type: DEVICE
Intervention: Cirrus HD-OCT 5000
Description: The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes

Intervention type: DEVICE
Intervention: Cirrus HD-OCT 5000
Description: The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes

Intervention type: DEVICE
Intervention: TRC-50DX
Description: The TRC-50DX retinal camera images the fundus used for diagnostic purposes

Intervention type: DEVICE
Intervention: TRC-50DX
Description: The TRC-50DX retinal camera images the fundus used for diagnostic purposes
Study: NCT04784208

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for Thyroid stimulating hormone (TSH)
Description: Blood test for Thyroid stimulating hormone (TSH)
Study: NCT05760417

Intervention type: OTHER
Intervention: Patient Participation Form
Description: A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
Study: NCT05850455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride 'Precedex' combined with
Description: Dexmedetomidine Hydrochloride which is an Alfa 2 receptor agonist

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar epidural analgesia with Bupivacaine 0.25% 'Sunnypivacaine'
Description: The epidural insertion point will be 2 segments upper than the surgical procedure level, 10 ml of Bupivacaine 0.25% will be injected in the epidural space to adjust the sensory level

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Propofol 2-3 mg/kg'Diprivan 1%', Fentanyl 'Fentanyl' 2 μg/kg, and Cisatracurium 'Cisatracure' 0.2 mg/kg will be administered to facilitate endotracheal intubation, and ventilation will be controlled to maintain the end-tidal carbon dioxide (CO2) between 32-38 mmHg, to maintain anesthesia, 2-3% Sevoflurane 'Sevoflurane', and 0.05 mg/kg of the muscle relaxant Cisatracurium will be added at 40-minute intervals according to the conditions of the operation. No other medication will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local infiltration with Lidocaine HCL 1%'Debocaine'
Description: Lidocaine 1% which is a local analgesic as local infiltration
Study: NCT05056909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kidney ACTion
Description: AI-supported software for chronic kidney disease care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study: NCT04882072

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: Participants will receive IV infusion and SC injection of ustekinumab.
Study: NCT05022758

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: One of NOAC (Non-vitamin K antagonist oral anticoagulants)

Intervention type: DRUG
Intervention: Warfarin
Description: One of OAC (Oral anticoagulation therapy)
Study: NCT04882072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive IV infusion and SC injection of ustekinumab.
Study: NCT04852029

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low dose hCG
Description: Patients will either maintain the current dose of have an increased dose prescribed based on randomization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose hCG
Description: Patients will either maintain the current dose of have an increased dose prescribed based on randomization